Tumor growth and angiogenesis is impaired in CIB1 knockout mice
© Zayed et al; licensee BioMed Central Ltd. 2010
Received: 17 April 2010
Accepted: 30 August 2010
Published: 30 August 2010
Pathological angiogenesis contributes to various ocular, malignant, and inflammatory disorders, emphasizing the need to understand this process more precisely on a molecular level. Previously we found that CIB1, a 22 kDa regulatory protein, plays a critical role in endothelial cell function, angiogenic growth factor-mediated cellular functions, PAK1 activation, MMP-2 expression, and in vivo ischemia-induced angiogenesis. Since pathological angiogenesis is highly dependent on many of these same processes, we hypothesized that CIB1 may also regulate tumor-induced angiogenesis.
To test this hypothesis, we allografted either murine B16 melanoma or Lewis lung carcinoma cells into WT and CIB1-KO mice, and monitored tumor growth, morphology, histology, and intra-tumoral microvessel density.
Allografted melanoma tumors that developed in CIB1-KO mice were smaller in volume, had a distinct necrotic appearance, and had significantly less intra-tumoral microvessel density. Similarly, allografted Lewis lung carcinoma tumors in CIB1-KO mice were smaller in volume and mass, and appeared to have decreased perfusion. Intra-tumoral hemorrhage, necrosis, and perivascular fibrosis were also increased in tumors that developed in CIB1-KO mice.
These findings suggest that, in addition to its other functions, CIB1 plays a critical role in facilitating tumor growth and tumor-induced angiogenesis.
Pathological angiogenesis is a hallmark of tumorigenesis and is a discrete event in solid tumor formation [1, 2]. Unlike physiological forms of angiogenesis that occur during embryonic development and normal wound healing, pathological, tumor-induced angiogenesis often ensues due to imbalances in either angiogenic activators or inhibitors [1, 3]. Recent pre-clinical and clinical studies have employed strategies to target tumor vasculature as a means to impede tumor growth and eventual metastasis [4, 5]. However, thus far monotherapy with such agents in human subjects has been limited due to marginal effectiveness, toxicities, and relative lack of specificity [6, 7]. Therefore, further exploration is currently underway for more specific drug targets that are not essential for physiological forms of angiogenesis.
CIB1 is a 22 kDa EF-hand-containing regulatory protein that was originally identified as a binding partner for the cytoplasmic tail of the platelet integrin αIIb, and later found to inhibit αIIbβ3 activation in megakaryocytes [8, 9]. Subsequently however, CIB1 was found to be widely expressed in various organs, tissues, and cell types, which suggested that it likely has additional uncharacterized roles [10, 11]. Accordingly, we and others have demonstrated that CIB1 binds to and regulates the activity of various proteins including the transcription factor PAX3 , the polo-like kinase Fnk and Snk , the inositol 1,4,5-triphosphate receptor , Rac3 , PAK1 , and FAK . Among these binding partners, PAK1 and FAK are known to regulate endothelial cell (EC) function in vitro, and contribute to angiogenesis in vivo [18–20]. Therefore, this connection led us to investigate whether CIB1 can also play a role in EC function and various forms of angiogenesis.
Recently, we reported that CIB1 is not required for developmental angiogenesis, as CIB1-KO mice are viable and female mice are fertile . However, CIB1 is essential for proper EC signaling and functions such as migration, proliferation, and nascent tubule formation . Loss of CIB1 in ECs also leads to attenuated responses to angiogenic growth factors such as VEGF and FGF-2, which result in decreased expression of the zinc-requiring matrix-degrading proteinase MMP-2. Moreover, CIB1-KO mice are impaired in pathological as well as adaptive forms of ischemia-induced angiogenesis, and PAK1 and ERK1/2 activation are significantly decreased in CIB1-KO ECs and ischemic muscle tissue . Although these data clearly demonstrate that CIB1 participates in ischemia-induced angiogenesis in vivo, its role in other forms of pathological angiogenesis, like tumor-induced angiogenesis is still unclear.
As in ischemia-induced angiogenesis, tumor-induced angiogenesis is highly dependent on angiogenic growth factors and MMPs [22–24]. Accordingly, tumor allografts in knockout mice for growth factors such as FGF-2 and MMPs such as MMP-2 and MMP-9 exhibit significantly reduced tumor growth and tumor-induced angiogenesis [1, 25, 26]. Since our previous studies demonstrated that CIB1-KO mice have decreased growth factor-mediated angiogenesis, and CIB1-KO ECs have attenuated MMP-2 expression, we hypothesized that CIB1-KO mice may also have a defect in tumor-induced angiogenesis. To test this conjecture we allografted CIB1-KO mice with murine tumor cells that endogenously expressed either very low levels (B16 melanoma tumor cells) or very high levels (Lewis lung carcinoma cells) of MMP-2, as previously demonstrated by zymography analysis . We report here that, in addition to regulating tumor growth, CIB1 in the host significantly contributes to tumor-induced angiogenesis.
Male WT and CIB1-KO mice between 15 and 18 weeks old were anesthetized with 1.125% isoflurane supplemented with 2:3 oxygen-air. Rectal temperature was closely maintained at 37.0 ± 0.5°C. Hair was removed from the hind-limb ventral adductor thigh region using depilating cream, with care to avoid erythema. Mice were given a single subcutaneous injection of either 5 × 105 B16 melanoma cells (purchased from UNC-CH Tissue Culture Facility) or 2.5 × 105 Lewis lung carcinoma cells (ATCC, Manassas, VA) that were impregnated in 50 μL of 50% growth factor reduced Matrigel. Tumor allografts were grossly inspected 14 days after tumor cell injections, and photographs were obtained to document differences in tumor morphology between WT and CIB1-KO mice (n = 8-11 mice per group). Gross tumor necrosis was defined by superficial discoloration of the tumor. Fourteen days after tumor cell injection, tumors were isolated from animals, and were weighed and then immersed in water to estimate the tumor volume.
Tumor fixation, histology, and capillary density assessment
Tumors isolated from animals were fixed in 2% PFA for 48 h, with a solution change at 24 h. Tumors were rinsed in water, placed in 70% ethanol for 48 h with shaking and another change of solution at 24 h. Four biopsies (~2-3 mm in size) were obtained from both the center and periphery of each tumor and embedded in paraffin. At least 3 interrupted sections, 6 μm thick and 50 μm apart, were obtained and stained with either H&E, or Masson's trichrome (MT), a marker for fibrosis-associated collagen deposition. For each tumor, one random interrupted section of all four biopsies was assessed for the incidence of necrosis or intra-tumoral bleeding, spanning 70% of the biopsy tissue section. Similarly, one random interrupted section of each biopsy was assessed for the incidence of perivascular fibrosis.
To assess capillary density, the plasma membranes of capillary ECs in tumor sections were labeled with Alexa Fluor 594-conjugated isolectin GSL-1-B4 (1:100; Invitrogen), or with primary rat anti-mouse CD31 (PECAM-1) antibody (1:50; Pharmingen) and subsequently Alexa Fluor 594-conjugated secondary goat anti-rat IgG (1:1000; Invitrogen). Using a Nikon TE2000U inverted fluorescent microscope with an OrcaER, four high magnification immunoflorescent and H&E images were collected for each biopsy to yield a total of 16 images per tumor specimen. Using ImageJ software, the number of vessels with a clear lumen and < 7 μm were counted by an independent observer, who was blinded as to animal genotypes. Tumor microvessel density was reported as the average number of microvessels per high-magnification frame.
Continuous variables were compared with the Student's t test. We considered P < 0.05 to be significant.
Results and Discussion
Almost all tumor cells secret angiogenic growth factors and MMPs (such as MMP-2 and MMP-9) to recruit and stimulate new blood vessel formation [1, 28]. Since we reported previously that CIB1-KO mouse tissue and ECs have reduced growth factor-induced angiogenesis and MMP-2 expression , we asked whether CIB1-KO mice also have a defect in tumor-induced angiogenesis. To address this question we subcutaneously injected the adductor hindlimb regions of WT and CIB1-KO mice with B16 melanoma tumor cells (which are known to secrete angiogenic growth factors such as VEGF, FGF-2, PDGF, but only very low levels of gelatinases MMP-2 and MMP-9), and Lewis lung carcinoma tumor cells (which, in addition to secreting various angiogenic growth factors, secrete higher levels of MMP-2 and MMP-9) .
Melanoma tumors have more gross necrosis in CIB1-KO mice.
Total Number of Mice
Mice with Tumor Necrosis
Mice with No Tumor Necrosis
% of Mice with Tumor Necrosis
B16 Melanoma Tumorsa
Lewis Lung Carcinoma Tumors
Interestingly, unlike the allografted melanoma tumors, none of the Lewis lung carcinoma tumors that developed in CIB1-KO and WT mice demonstrated evidence of gross morphological necrosis (Table 1 and Figure 1a). Compared to melanoma tumors, the complete lack of gross necrosis in carcinoma tumor in CIB1-KO mice may be due to differences in the physiology and cellular metabolic demand of Lewis lung carcinoma cells. Alternatively, this difference may be attributed to the ability of Lewis lung carcinoma cells to express and secrete high levels of MMP-2, which does not occur as effectively in B16 melanoma cells. Nevertheless, similar to melanoma tumors in CIB1-KO mice, Lewis lung carcinomas were also 30% reduced in weight and 35% reduced in volume when compared to these carcinomas in WT mice (p = 0.02 and 0.008, respectively; Figure 1b and 1c).
Moreover, carcinomas in CIB1-KO mice also appeared more blanched (Figure 1a), which suggested that these tumors were not as well perfused. To measure perfusion in Lewis Lung carcinoma tumors we used a non-invasive Doppler flowmeter for periodic assessment of tumor perfusion in real-time. Doppler perfusion of melanoma tumors in CIB1-KO mice was not assessed since they appeared to be grossly necrotic in appearance. Doppler images of 14 day old carcinomas demonstrated areas of clearly higher tumor perfusion in WT, but not CIB1-KO mice (areas in white; Additional file 1: Figure 1a). Quantification of these data also demonstrated a trend of reduced carcinoma tumor perfusion in CIB1-KO mice. However, due to variations in tumor dimensions and orientation, no overall statistically significant differences were extrapolated from this analysis (Additional file 1: Figure 1b). Nevertheless, like melanoma allografts, the decreased size and differences in carcinoma allograft gross appearance in CIB1-KO mice suggest that these tumors were not growing as efficiently as carcinomas in WT mice.
The decreased microvessel density in allografted tumors in CIB1-KO mice may be due to decreased expression and secretion of MMP-2 by CIB1-KO ECs, which we reported previously . Itoh et al. (1998) demonstrated that MMP-2-KO mice have decreased tumor growth and metastasis. In accordance with our observations, the study also reported that MMP-2-KO mice have significantly decreased B16 melanoma and Lewis lung carcinoma allograft tumor growth. Since this decrease in tumor growth was largely unaffected by the difference in expression of MMP-2 by melanoma and carcinoma cells, the authors concluded that host-derived MMP-2 has a critical role in tumor progression and angiogenesis. Likewise, melanoma tumors in CIB1-KO mice have significantly decreased tumor-derived and host-derived MMP-2. Minimal MMP-2 would at least in part explain the decrease observed in allograft tumor growth and neovascularization in CIB1-KO mice. In addition, it would also suggest an alternative explanation for why a higher incidence of gross and histological necrosis was noted in melanomas, but not in carcinomas that have high levels of tumor-derived MMP-2 and low levels of host-derived MMP2.
The combination of increased tumor necrosis and decreased tumor-induced angiogenesis in CIB1-KO mice may also be a direct result of attenuated EC signaling in these mice. As previously reported, ECs deficient in CIB1 have reduced PAK1 activation. The activation of this serine/threonine kinase is an important point of convergence between growth factor- and integrin-induced signaling that is mediated by small GTP-bound GTPases such as Cdc42 [30, 31]. Leisner et al. demonstrated that CIB1 binds to PAK1, thus preventing its interaction with Cdc42 and subsequent activation in various cell types . Since PAK1 primarily mediates its effects on ECs via the Ras-Raf-ERK1/2 MAPK signaling pathway , we previously tested whether MAPK signaling is affected when CIB1 is not present. ERK1/2, but not p38, MAPK signaling was significantly attenuated in CIB1-KO ECs in vitro, and in CIB1-KO ischemic and non-ischemic muscles in vivo . Thus, a CIB1-mediated inhibition of the PAK1-ERK1/2 pathway may explain the decrease noted in tumor-induced angiogenesis in CIB1-KO mice. Further studies are currently underway to determine if PAK1 downstream targets such as MMP-9 and TIMP-1 are also affected by levels of CIB1 expression.
There may also be alternative mechanisms by which CIB1 mediates its effects on tumor growth and neovascularization. We have observed decreased monolayer resistance in CIB1-KO ECs (unpublished data), suggesting that CIB1 is necessary for proper EC monolayer permeability in vitro. Related to this observation, in preliminary analysis of gene array studies we found that PECAM1 was among the most significantly downregulated genes in CIB1-KO ECs (p = 0.017, unpublished data). Not only is PECAM1 important for maintaining EC monolayer integrity, but it also plays an essential role in tumor growth and metastasis [32, 33]. For example, local administration of anti-murine antibodies targeting EC-expressed PECAM1 inhibits both growth factor- and tumor-induced angiogenesis in vivo . Thus, like PECAM-KO mice (which are fertile and viable; Duncan et al., 1999), CIB1-KO mice may also have an underlying endothelial permeability defect that does not manifest overtly, but affects pathological tumor growth. Such defects in CIB1-KO ECs would play a large part in the increased gross and microscopic allograft tumor bleeding observed in our study. Further studies are currently underway to characterize the nature of these defects and the implications they have on both physiological and other pathological processes.
Taken together, our findings support a model in which CIB1 plays an important role in regulating tumor viability, growth, and angiogenesis. We propose that CIB1 mediates these effects at least in part through its previously characterized role in PAK1-ERK1/2-MMP-2 signaling. The fact that more necrosis and bleeding was noted in melanoma tumors in CIB1-KO mice, where there is a relative lack of MMP-2, suggests that this mechanism may be a major pathway mediating the observed effects in this study. Hence the data herein establish a regulatory role for CIB1 in tumor growth and pathological tumor-induced angiogenesis.
MAZ carried out these studies in partial fulfillment for the PhD degree while enrolled in the MD/PhD program at UNC-CH. MAZ is currently a vascular surgery resident at Stanford University Medical Center.
WY created the CIB1 knockout mice and is an expert molecular biologist.
DC is a postdoctoral research associate in the Department of Cell and Molecular Physiology at UNC-CH.
JEF is a full professor in the Department of Cell and Molecular Physiology at UNC-CH. He is expert in physiologic and genetic regulation of collaterogeneis and angiogenesis during development and disease, as well as in vascular wall growth and remodeling.
LVP was the thesis advisor for MAZ. She is also full professor and Chair of the Department of Biochemistry and Biophysics at UNC-CH. Her lab originally discovered CIB1 and she is an expert on integrin mediated adhesion and signal transduction in vascular cells.
List of Abbreviations
calcium and integrin binding protein 1
p21 activated kinase 1
focal adhesion kinase
vascular endothelial growth factor
basic fibroblast growth factor 2
University of North Carolina Chapel Hill
Hematoxylin and Eosin
We thank Kirt McNaughton for assistance with tissue sectioning and staining, the UNC-CH Michael Hooker Microscopy Facility for imaging assistance, and Dr. William Barry for preliminary microarray data analysis. We also thank Dr. Howard Fried for editorial suggestions. This work was supported by grants from NIH 2-P01-HL45100 and 1RO1HL092544 (L. V. Parise), NIH HL-62584 (J. E. Faber), NIH T32-HL-069768 and NIH T32-GM008719 (M. A. Zayed).
- Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407: 249-257. 10.1038/35025220.View ArticlePubMed
- Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016/S0092-8674(00)80108-7.View ArticlePubMed
- Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 2005, 438: 932-936. 10.1038/nature04478.View ArticlePubMed
- O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996, 2: 689-692. 10.1038/nm0696-689.View ArticlePubMed
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350: 2335-2342. 10.1056/NEJMoa032691.View ArticlePubMed
- Gordon MS, Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology. 2005, 69 (Suppl 3): 25-33. 10.1159/000088481.View ArticlePubMed
- Quesada AR, Munoz-Chapuli R, Medina MA: Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev. 2006, 26: 483-530. 10.1002/med.20059.View ArticlePubMed
- Naik UP, Patel PM, Parise LV: Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem. 1997, 272: 4651-4654. 10.1074/jbc.272.8.4651.View ArticlePubMed
- Yuan W, Leisner TM, McFadden AW, Wang Z, Larson MK, Clark S, et al: CIB1 is an endogenous inhibitor of agonist-induced integrin alphaIIbbeta3 activation. J Cell Biol. 2006, 172: 169-175. 10.1083/jcb.200505131.PubMed CentralView ArticlePubMed
- Saito T, Seki N, Hattori A, Hayashi A, Abe M, Araki R, et al: Structure, expression profile, and chromosomal location of a mouse gene homologous to human DNA-PKcs interacting protein (KIP) gene. Mamm Genome. 1999, 10: 315-317. 10.1007/s003359900994.View ArticlePubMed
- Shock DD, Naik UP, Brittain JE, Alahari SK, Sondek J, Parise LV: Calcium-dependent properties of CIB binding to the integrin alphaIIb cytoplasmic domain and translocation to the platelet cytoskeleton. Biochem J. 1999, 342 (Pt 3): 729-735. 10.1042/0264-6021:3420729.PubMed CentralView ArticlePubMed
- Hollenbach AD, McPherson CJ, Lagutina I, Grosveld G: The EF-hand calcium-binding protein calmyrin inhibits the transcriptional and DNA-binding activity of Pax3. Biochim Biophys Acta. 2002, 1574: 321-328.View ArticlePubMed
- Kauselmann G, Weiler M, Wulff P, Jessberger S, Konietzko U, Scafidi J, et al: The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J. 1999, 18: 5528-5539. 10.1093/emboj/18.20.5528.PubMed CentralView ArticlePubMed
- White C, Yang J, Monteiro MJ, Foskett JK: CIB1, a ubiquitously expressed Ca2+-binding protein ligand of the InsP3 receptor Ca2+ release channel. J Biol Chem. 2006, 281: 20825-20833. 10.1074/jbc.M602175200.View ArticlePubMed
- Haataja L, Kaartinen V, Groffen J, Heisterkamp N: The small GTPase Rac3 interacts with the integrin-binding protein CIB and promotes integrin alpha(IIb)beta(3)-mediated adhesion and spreading. J Biol Chem. 2002, 277: 8321-8328. 10.1074/jbc.M105363200.View ArticlePubMed
- Leisner TM, Liu M, Jaffer ZM, Chernoff J, Parise LV: Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol. 2005, 170: 465-476. 10.1083/jcb.200502090.PubMed CentralView ArticlePubMed
- Naik MU, Naik UP: Calcium-and integrin-binding protein regulates focal adhesion kinase activity during platelet spreading on immobilized fibrinogen. Blood. 2003, 102: 3629-3636. 10.1182/blood-2003-05-1703.View ArticlePubMed
- Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA: Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003, 162: 933-943. 10.1083/jcb.200304105.PubMed CentralView ArticlePubMed
- Kiosses WB, Hood J, Yang S, Gerritsen ME, Cheresh DA, Alderson N, et al: A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res. 2002, 90: 697-702. 10.1161/01.RES.0000014227.76102.5D.View ArticlePubMed
- Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, et al: Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 2005, 169: 941-952. 10.1083/jcb.200411155.PubMed CentralView ArticlePubMed
- Zayed MA, Yuan WP, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, et al: CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circulation Research. 2007, 101: 1185-1193. 10.1161/CIRCRESAHA.107.157586.View ArticlePubMed
- Jain RK: Molecular regulation of vessel maturation. Nat Med. 2003, 9: 685-693. 10.1038/nm0603-685.View ArticlePubMed
- Lemaitre V, D'Armiento J: Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today. 2006, 78: 1-10. 10.1002/bdrc.20065.View ArticlePubMed
- Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 2000, 407: 242-248. 10.1038/35025215.View ArticlePubMed
- Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58: 1048-1051.PubMed
- Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000, 2: 737-744. 10.1038/35036374.PubMed CentralView ArticlePubMed
- Nasu R, Kimura H, Akagi K, Murata T, Tanaka Y: Blood flow influences vascular growth during tumour angiogenesis. Br J Cancer. 1999, 79: 780-786. 10.1038/sj.bjc.6690125.PubMed CentralView ArticlePubMed
- Bjorklund M, Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005, 1755: 37-69.PubMed
- Kato Y, Nakayama Y, Umeda M, Miyazaki K: Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem. 1992, 267: 11424-11430.PubMed
- Beeser A, Jaffer ZM, Hofmann C, Chernoff J: Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem. 2005, 280: 36609-36615. 10.1074/jbc.M502306200.View ArticlePubMed
- Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L: A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994, 367: 40-46. 10.1038/367040a0.View ArticlePubMed
- DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, et al: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997, 151: 671-677.PubMed CentralPubMed
- Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H, Spellberg J, et al: Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM -1- dependent and PECAM-1-independent functions. J Immunol. 1999, 162: 3022-3030.PubMed
- Zhou Z, Christofidou-Solomidou M, Garlanda C, DeLisser HM: Antibody against murine PECAM-1 inhibits tumor angiogenesis in mice. Angiogenesis. 1999, 3: 181-188. 10.1023/A:1009092107382.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.